

COMMITTEE PRINT

[SHOWING TEXT OF H.R. 2408 AS FORWARDED BY THE SUBCOMMITTEE
ON HEALTH ON SEPTEMBER 16, 2010]

111TH CONGRESS
1ST SESSION

H. R. 2408

To expand the research and awareness activities of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the Centers for Disease Control and Prevention with respect to scleroderma, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

MAY 14, 2009

Mrs. CAPPS (for herself, Mr. EHLERS, Mr. HINCHEY, Mr. MASSA, Mr. MCGOVERN, Mr. MOORE of Kansas, Mr. MURPHY of Connecticut, Ms. LINDA T. SÁNCHEZ of California, Mr. STEARNS, and Mr. TONKO) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To expand the research and awareness activities of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the Centers for Disease Control and Prevention with respect to scleroderma, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Scleroderma Research
3 and Awareness Act of 2010”.

4 **SEC. 2. NATIONAL INSTITUTE OF ARTHRITIS AND MUS-
5 CULOSKELETAL AND SKIN DISEASES;
6 SCLERODERMA RESEARCH EXPANSION.**

7 Part B of title IV of the Public Health Service Act
8 (42 U.S.C. 284 et seq.) is amended by adding at the end
9 the following:

10 “SCLERODERMA RESEARCH

11 “SEC. 409K. The Director of NIH may expand, in-
12 tensify, and coordinate the activities of the National Insti-
13 tutes of Health with respect to scleroderma, with par-
14 ticular emphasis on the following:

15 “(1) Research focused on the etiology of
16 scleroderma and the development of new treatment
17 options.

18 “(2) Clinical research to evaluate new treat-
19 ments options.

20 “(3) Basic research on the relationship between
21 scleroderma and secondary conditions such as pul-
22 monary hypertension, gastroparesis, Raynaud’s phe-
23 nomenon, Sjögren’s Syndrome, and other diseases as
24 determined by the Director.”.

1 **SEC. 3. PROMOTING PUBLIC AWARENESS OF**
2 **SCLERODERMA.**

3 Part P of the Public Health Service Act (42 U.S.C.
4 280g et seq.) is amended by adding at the end the fol-
5 lowing:

6 **“SEC. 399V-5. PROMOTING PUBLIC AWARENESS OF**
7 **SCLERODERMA.**

8 “The Secretary may carry out an educational cam-
9 paign to increase public awareness of scleroderma. Print,
10 video, and Web-based materials distributed through this
11 campaign may include—

12 “(1) basic information on scleroderma and its
13 symptoms; and

14 “(2) information on—

15 “(A) the incidence and prevalence of
16 scleroderma;

17 “(B) diseases and conditions affiliated with
18 scleroderma; or

19 “(C) the importance of early diagnosis and
20 treatment of scleroderma.”.